Cite
HARVARD Citation
Lasater, E. et al. (2023). Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. American journal of hematology. 98 (3), pp. 449-463. [Online].